Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Document Type

Article

Publication Date

10-2019

Identifier

DOI: 10.1002/cpt.1477; PMCID: PMC6739160

Abstract

The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.

Journal Title

Clinical pharmacology and therapeutics

Volume

106

Issue

4

First Page

726

Last Page

733

MeSH Keywords

Anti-HIV Agents; Benzoxazines; Cytochrome P-450 CYP2B6; HIV Infections; HIV-1; Humans; Pharmacogenetics; Pharmacogenomic Testing; Practice Guidelines as Topic

Keywords

Anti-HIV Agents; Benzoxazines; Cytochrome P-450 CYP2B6; HIV Infections; HIV-1; Humans; Pharmacogenetics; Pharmacogenomic Testing; Practice Guidelines as Topic

Link to Full Text
Library Record

Share

COinS